Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study.
Daniel H TajchmanHafsah NabiMohsin AslamJawad H ButtErik Lerkevang GroveThomas EngstrømLene HolmvangEmil Loldrup FosboelLars Valeur KøberRikke SørensenPublished in: European heart journal. Acute cardiovascular care (2021)
Initiation of P2Y12 inhibitors in PCI-treated MI patients was high in contrast to those treated with CABG or MTA and patients with certain comorbidities. Further studies on the benefit-risk ratio of P2Y12 inhibitors in CABG-treated or MTA-treated patients and patients with comorbidities after first-time MI are warranted, as is focus on persistence among patients receiving MTA, patients with comorbidities, and users of ticagrelor.
Keyphrases
- newly diagnosed
- end stage renal disease
- chronic kidney disease
- ejection fraction
- percutaneous coronary intervention
- acute coronary syndrome
- coronary artery bypass grafting
- prognostic factors
- heart failure
- peritoneal dialysis
- acute myocardial infarction
- magnetic resonance imaging
- atrial fibrillation
- st segment elevation myocardial infarction
- antiplatelet therapy
- contrast enhanced